NCT06412289 Comparison of the Diagnostic Accuracy: US-guided Percutaneous Lung Biopsies vs CT-guided in Peripheral Lung Lesions
| NCT ID | NCT06412289 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital of Ferrara |
| Condition | Peripheral Lung Lesions |
| Study Type | INTERVENTIONAL |
| Enrollment | 236 participants |
| Start Date | 2024-03-08 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 236 participants in total. It began in 2024-03-08 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A non-sponsored prospective randomized single-blind national multicenter interventional study which aims to compare the diagnostic accuracy between US-guided percutaneous lung needle biopsies and CT-guided in peripheral lung lesions. Secondary endpoints are: * onset of number and type of complications during and after the procedure, within the first three hour; * exposition to ionizing radiation, in milligray(mGy); * patient comfort during the procedure; * duration of the procedure,
Eligibility Criteria
Inclusion Criteria: * Willingness and ability to provide free and informed consent. Age older then 18 years old. * Peripheric pulmonary lesions adherent to the thoracic wall in CT scans with indication to typing Exclusion Criteria: * Inability to provide free and informed consent, in the absence of an available legal guardian. * Age younger then 18 years old. * Terminal neoplastic diseases/ palliative care patients. * Patients with one lung, anatomical of functional. * Severe non-treatable blood clothing disfunctions. * Severe organ failure (pulmonary, renal, hepatic or cardiac). * Women in state of pregnancy.
Contact & Investigator
Mario Tamburrini, Dr.
PRINCIPAL INVESTIGATOR
Arcispedale Sant'Anna
Frequently Asked Questions
Who can join the NCT06412289 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Peripheral Lung Lesions. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06412289 currently recruiting?
Yes, NCT06412289 is actively recruiting participants. Contact the research team at ludovica.rizzo14@gmail.com for enrollment information.
Where is the NCT06412289 trial being conducted?
This trial is being conducted at Ferrara, Italy, Naples, Italy.
Who is sponsoring the NCT06412289 clinical trial?
NCT06412289 is sponsored by University Hospital of Ferrara. The principal investigator is Mario Tamburrini, Dr. at Arcispedale Sant'Anna. The trial plans to enroll 236 participants.